Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Inhaled Fluticasone on Exercise in COPD
NCT00387036Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Dec 2006
- Primary completion
- Jul 2009
- Modality
- Orthosteric Ligands
01
Overview
Phase 2, randomised, double-blind trial of fluticasone propionate nasal spray in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Merck & Co. Primary endpoint: Standardized Dyspnea Score at Isotime During Exercise at 2 weeks. Started Dec 2006; status: terminated.
02
Drugs
fluticasone propionate nasal spray
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00387036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00387036.